PARTNERING

Alliances

	Xencor has entered into an option agreement with Amgen for worldwide rights to XmAb®5871, a monoclonal antibody dually targeting CD19 and CD32b to inhibit autoimmune diseases. Xencor will lead development through the first Phase 2 trial.
	Xencor is collaborating with Pfizer using Xencor’s Xtend™ half-life prolongation technology and XmAb® ADCC enhancing technology to optimize performance of the company’s therapeutic monoclonal antibodies.
	Xencor is collaborating with Centocor using Xencor’s Xtend™ half-life prolongation technology and XmAb® ADCC enhancing technology to optimize performance of the company’s therapeutic monoclonal antibodies.
	MorphoSys has licensed worldwide rights for XmAb® 5574, a B-cell targeting antibody with XmAb® ADCC enhancing technology. Xencor and MorphoSys are collaborating for the clinical development of XmAb5574 in oncology and autoimmune diseases.
	Xencor is collaborating with Boehringer Ingelheim to create monoclonal antibodies with greatly enhanced potency. Boehringer Ingelheim will use Xencor’s XmAb® engineered Fc’s to improve antibodies against select Boehringer Ingelheim.
	Xencor is collaborating with CSL Ltd. to provide access to Xencor’s XmAb® technology platform to enhance the ADCC effector function of its therapeutic antibodies.
	Xencor is collaborating with Human Genome Sciences to humanize a portfolio of monoclonal antibodies and to improve their potency. We are using our proprietary XmAb® Fv and Fc technologies to create antibody candidates against select Human Genome Sciences target